Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) EBT Margin (2020 - 2025)

Barinthus Biotherapeutics' EBT Margin history spans 6 years, with the latest figure at 2115100.0% for Q2 2025.

  • For Q2 2025, EBT Margin changed N/A year-over-year to 2115100.0%; the TTM value through Dec 2025 reached 21019.87%, down 2061085.0%, while the annual FY2024 figure was 409.03%, 913237.0% up from the prior year.
  • EBT Margin reached 2115100.0% in Q2 2025 per BRNS's latest filing, down from 6227.85% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 1668600.0% in Q4 2021 to a low of 2115100.0% in Q2 2025.
  • Average EBT Margin over 5 years is 41981.97%, with a median of 4004.06% recorded in 2023.
  • Peak YoY movement for EBT Margin: skyrocketed 167206441bps in 2021, then tumbled -166895902bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 1668600.0% in 2021, then plummeted by -100bps to 359.02% in 2022, then plummeted by -1982bps to 7473.05% in 2023, then surged by 99bps to 54.33% in 2024, then tumbled by -3893276bps to 2115100.0% in 2025.
  • Per Business Quant, the three most recent readings for BRNS's EBT Margin are 2115100.0% (Q2 2025), 6227.85% (Q1 2025), and 54.33% (Q3 2024).